Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 Jun 29;27(16):4557–4565. doi: 10.1158/1078-0432.CCR-21-0585

Figure 4. Association of changes in tumor immune microenvironment after cemiplimab treatment with pathological responses.

Figure 4.

CyTOF analysis of pre-and post-treatment tumor specimens. (A) Dot plot showing percentage of a memory CD8-T cell subset (CD8+Eomes+CD45RO+) in pre-and post-treatment tumor specimens of patients with pathologic complete response (pCR) and pathologic nonresponders (NR, pathologic stable or progressive disease). (B–C) Dot plots showing percentages of (B) regulatory T cells (CD3+CD4+FOXP3+) and (C) a myeloid cell subset expressing inhibitory marker VISTA (CD68+CD14+VISTA+) in pre-and post-treatment tumor specimens of patients with pathologic response and NR. P<0.05 denotes statistically significant changes.